Leukemia, Lymphocytic, Chronic, B-Cell
Showing NaN - NaN of 9
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (JNJ-75348780)
Recruiting
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, Chronic, B-Cell
-
Birmingham, Alabama
- +43 more
Jan 27, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic Trial in United States (JCAR017 (lisocabtagene maraleucel),
Active, not recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Small Lymphocytic
- JCAR017 (lisocabtagene maraleucel)
- +2 more
-
Birmingham, Alabama
- +63 more
Nov 21, 2022
Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia Trial in Worldwide (MT-3724
Terminated
- Non-Hodgkin's B-cell Lymphoma
- +5 more
- MT-3724 Phase 1
- MT-3724 Phase 2
-
Tucson, Arizona
- +40 more
Jul 18, 2022
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Lymphocytic, Small, Lymphoma, Mantle-Cell Trial in Worldwide (Pirtobrutinib)
Available
- Leukemia, Lymphocytic, Chronic, B-Cell
- +4 more
-
Stanford, California
- +61 more
Aug 17, 2022
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma Trial in Worldwide (BMS-986403, Fludarabine, Cyclophosphamide)
Recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma
- BMS-986403
- +2 more
-
Birmingham, Alabama
- +24 more
Jul 6, 2022
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (Durvalumab, Lenalidomide, Rituximab)
Active, not recruiting
- Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Durvalumab
- +4 more
-
Gilbert, Arizona
- +53 more
Jan 25, 2022
Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (CC-122, Ibrutinib, Obinutuzumab)
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
- CC-122
- +2 more
-
La Jolla, California
- +23 more
Aug 20, 2021
Leukemia, Lymphocytic, Chronic, B-Cell Trial in Houston (INVAC-1)
Terminated
- Leukemia, Lymphocytic, Chronic, B-Cell
- INVAC-1
-
Houston, TexasMD Anderson Cancer Center
Jul 6, 2020
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular Trial in Worldwide (Part 1 (Dose
Terminated
- Leukemia, Lymphocytic, Chronic, B-Cell
- +4 more
- Part 1 (Dose Escalation): Duvortuxizumab
- Part 2 (Dose Expansion): Duvortuxizumab
-
Detroit, Michigan
- +19 more
Dec 19, 2018